Tumor necrosis factor (TNF) and Lymphotoxin-alpha (LTA) (TNF and LTA)

Tumor necrosis factor (TNF, or TNF-alpha) and Lymphotoxin-alpha (LTA, or TNF-beta) are pivotal pro-inflammatory cytokines that regulate a wide array of biological processes, including immune cell activation, apoptosis, and the acute phase response (UniProt P01375, P01374). These proteins exert their effects by binding to two distinct cell-surface receptors, TNFR1 and TNFR2, triggering signaling pathways like NF-kappaB that drive inflammatory gene expression. Dysregulation and chronic elevation of TNF levels are central to the pathogenesis of numerous autoimmune and inflammatory diseases, leading to tissue destruction and systemic symptoms in conditions like rheumatoid arthritis and plaque psoriasis. Etanercept is a recombinant therapeutic fusion protein designed to mimic the ligand-binding domain of the human p75 TNF receptor. By acting as a soluble decoy, it competitively binds to both TNF-alpha and TNF-beta, effectively neutralizing their ability to initiate inflammatory signaling. This mechanism provides significant clinical benefit by reducing the systemic inflammatory burden and slowing disease progression in chronic inflammatory states (StatPearls, 2023). Unlike monoclonal antibodies that specifically target TNF-alpha, etanercept's ability to bind both TNF-alpha and TNF-beta distinguishes its pharmacological profile within the class of TNF inhibitors.

Other names

TNF-alphaTNF-betaTumor necrosis factor-alphaTumor necrosis factor-betaTumor necrosis factor ligand superfamily member 2Tumor necrosis factor ligand superfamily member 1TNFSF2TNFSF1Cachectin

Etanercept is a dimeric fusion protein that functions as a soluble decoy receptor. It consists of the extracellular ligand-binding portion of the human 75 kDa (p75) tumor necrosis factor receptor (TNFR2) linked to the Fc portion of human IgG1. It competitively binds to and neutralizes both circulating Tumor Necrosis Factor-alpha (TNF-alpha) and Lymphotoxin-alpha (TNF-beta), preventing their interaction with cell-surface TNF receptors (TNFR1 and TNFR2). This blockade effectively inhibits the downstream pro-inflammatory signaling cascades, such as the NF-kappaB and MAPK pathways, which are responsible for the production of inflammatory cytokines and joint destruction in autoimmune diseases (StatPearls, 2023; FDA Label).